App-Quantinova.ai

Association of nuclear localization of SATB1 with adverse clinical outcome in breast cancer.

Weiming Duan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Progesterone receptor, a novel risk factor for paclitaxel-induced peripheral neuropathy.

Zohreh Ghoreishi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

estrogen + progesterone

PIK3CA mutational status and correlation with tumor glycolysis imaged with [18F]FDG PET/CT in early primary ER+ / HER2- breast cancer patients: a feasibility study.

Heinrich Florian Magometschnigg - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Eight years retrospective analysis of the racial differences in hormone receptor status in lobular carcinoma of the breast in a community cancer center.

Jean Gabriel Bustamante Alvarez - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Olexiy Aseyev - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Trastuzumab

Time to definitive deterioration in patients with metastatic breast cancer subjected to second-line monochemotherapy.

Miguel Angel Segui-Palmer - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Neoadjuvant cisplatin and doxorubicin in locally advanced triple negative breast cancer.

Abdul Mateen - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Doxorubicin

Multicenter, phase II open-label trial of percutaneous laser ablation (PLA) for 61 patients (pts) with early-stage (ES) primary breast cancer: Radiographic (MRI) and pathological correlation.

Barbara Stewart Schwartzberg - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Phase II study on radiofrequency ablation in early breast cancer.

Shigeru Imoto - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Influence of obesity on survival in non-metastatic triple negative breast cancer; a retrospective analysis.

Suman Paul - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

taxane

Metaplastic carcinoma of the breast, clinico-pathological and prognosis comparison with triple negative breast carcinoma: Experience of the Kuwait Cancer Control Center.

Mohamed Salah Fayaz - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Phase 1/2 study of glucocorticoid receptor (GR) antagonist mifepristone (MIFE) in combination with eribulin (E) in advanced solid tumors, with dose expansion in patients with GR-positive (GR+) triple-negative breast cancer (TNBC).

Sharon Wilks - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Glucocorticoid

Targeting the Achilles' shield of triple-negative breast carcinoma by androgen blockade.

Mohamed Abazeed - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Androgen Tear

Genomic diversity in established melanoma cell lines and human melanoma tumors.

Polina Shindiapina - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

ERASE: Elimination of recurring artifacts and stochastic errors: An NGS analysis approach and its application to liquid biopsy samples.

Nicholas Kamps-Hughes - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Frequency of variants of uncertain significance in BRCA1 and BRCA2 in an Irish cohort.

Michael P. Farrell - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Cancer characteristics of male BRCA mutation carriers in a Cancer Genetics Clinic database: The Beaumont Health System experience.

Mohammed Ibrahim - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Duplicate genetic testing in families: The need for a health identifier solution.

David James Gallagher - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Patient awareness and expectations of tumor genomic profiling (TGP) may predict willingness-to-pay (WTP) in a diverse patient sample.

John M. Kaczmar - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Killer-cell Inmunoglobulin-like Receptor (KIR) genes as a predictor of response to the anti-HER therapy in solid tumors.

Cristina Morales-Estevez - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Trastuzumab

Filters

41730 Abstracts